Хайлтын үр дүнгүүд - David R. Spigel
- 121-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts -н Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel
Хэвлэсэн 2011Revisão -
9
-
10
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the... -н John D. Hainsworth, Mark S. Rubin, David R. Spigel, Ralph V. Boccia, Samuel Raby, Raven Quinn, F. Anthony Greco
Хэвлэсэн 2012Artigo -
11
High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History -н Bert H. O’Neil, Robert M. Allen, David R. Spigel, Thomas E. Stinchcombe, Dominic T. Moore, Jordan Berlin, Richard M. Goldberg
Хэвлэсэн 2007Artigo -
12
Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site -н John D. Hainsworth, David R. Spigel, Dana S. Thompson, Patrick Murphy, Cassie M. Lane, David Waterhouse, Yuval Naot, F. Anthony Greco
Хэвлэсэн 2009Artigo -
13
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer -н John D. Hainsworth, David R. Spigel, C. Farley, Dianna Shipley, James D. Bearden, Jitendra G. Gandhi, Gerry Ann Houston, F. Anthony Greco
Хэвлэсэн 2007Artigo -
14
PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 -н Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
Хэвлэсэн 2016Artigo -
15
P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 -н Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck
Хэвлэсэн 2016Artigo -
16
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer -н David R. Spigel, F. Anthony Greco, John D. Zubkus, Patrick Murphy, Ruben A. Saez, C. Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth
Хэвлэсэн 2009Artigo -
17
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial -н David R. Spigel, P. Townley, David Waterhouse, Fang Ting Liang, İbrahim Adıgüzel, Jane E. Huang, David A. Karlin, Leonardo Faoro, Frank A. Scappaticci, Mark A. Socinski
Хэвлэсэн 2011Artigo -
18
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung -н David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok
Хэвлэсэн 2017Artigo -
19
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor... -н Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff
Хэвлэсэн 2016Artigo -
20
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study -н John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock
Хэвлэсэн 2018Artigo
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Immunotherapy
Chemotherapy
Nivolumab
Clinical endpoint
Surgery
Confidence interval
Hazard ratio
Gastroenterology
Pathology
Randomized controlled trial
Cancer research
Clinical trial
Adverse effect
Environmental health
Pembrolizumab
Population
Biology
Alternative medicine
Placebo
Cisplatin
Phases of clinical research
Colorectal cancer
Epidermal growth factor receptor
Atezolizumab
Bevacizumab